Diabetic Gastroparesis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for diabetic gastroparesis. 7 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
7
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Diabetic Gastroparesis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Hikma 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating diabetic gastroparesis. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
29
1
30
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Reglan
Metoclopramide Hydrochloride
 Hikma 7 75 — 2029-12-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12194008 Reglan method of use 81 2029-12-22
12194009 Reglan method of use 81 2029-12-22
11628150 Reglan method of use 76 2029-12-22
11813231 Reglan method of use 76 2029-12-22
12377064 Reglan method of use 75 2038-11-17
11020361 Reglan method of use 68 2029-12-22
8334281 Reglan method of use 68 2030-05-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8334281 Reglan method of use 68 2030-05-16
11020361 Reglan method of use 68 2029-12-22
12377064 Reglan method of use 75 2038-11-17
11813231 Reglan method of use 76 2029-12-22
11628150 Reglan method of use 76 2029-12-22
12194009 Reglan method of use 81 2029-12-22
12194008 Reglan method of use 81 2029-12-22

Related